Mounjaro
The brand name for tirzepatide — a dual GIP/GLP-1 medication approved for type 2 diabetes. Targets two gut hormones for stronger blood sugar and weight control.
Mounjaro is the brand name for tirzepatide, a weekly injection that targets two gut hormones (GIP and GLP-1) instead of one. It's approved for type 2 diabetes and produces significant weight loss — up to 22.5% in clinical trials.
Good for you if: You have type 2 diabetes not well controlled on current medications, or your doctor recommends a dual-action GLP-1 medication for better blood sugar and weight management.
Dive deeper into the researchCommon side effects
- Nausea in 25–35% of users — usually fades with slow titration
- GI side effects (diarrhoea, constipation) are dose-dependent
- Same serious risk profile as other GLP-1 drugs (pancreatitis, gallbladder)
What does Mounjaro do?
Mounjaro contains tirzepatide, which mimics two gut hormones — GLP-1 and GIP — that your body normally releases after eating. This dual action gives you better appetite control, stronger insulin response, and more effective fat metabolism than medications that target only one of these pathways.
In clinical trials, people on Mounjaro saw HbA1c drop by 2.0–2.4% and lost 12–22% of their body weight depending on the dose.
Who is it for?
Mounjaro is approved in India for type 2 diabetes in adults. Like Ozempic, it also causes significant weight loss, so doctors sometimes prescribe it when both blood sugar control and weight management are goals.
- Adults with type 2 diabetes not adequately controlled on metformin
- People who want dual benefit of blood sugar + weight management
- Patients whose doctor recommends stepping up from a GLP-1-only medication
How it's taken
Start at 2.5 mg/week for 4 weeks, then increase to 5 mg. Your doctor may titrate up to 7.5 mg, 10 mg, 12.5 mg, or 15 mg based on response and tolerance.
Inject once weekly in your stomach, thigh, or upper arm. Same day each week, any time of day.
Availability in India
Mounjaro is manufactured by Eli Lilly and is available in India with a prescription. It's becoming more widely stocked but isn't as ubiquitous as Ozempic yet. Cost is approximately ₹8,000–₹18,000 per month depending on dose. Available at major pharmacies and endocrinology clinics in metropolitan areas.
Track your GLP-1 biomarkers with eterni
HbA1c, fasting insulin, body composition, and more — monitored over time so you can see if your protocol is working.
Get early accessFrequently Asked Questions
What is the difference between Mounjaro and Ozempic?
Mounjaro contains tirzepatide (dual GIP/GLP-1 agonist) while Ozempic contains semaglutide (GLP-1 only). In head-to-head trials, tirzepatide produced more weight loss and equivalent or better blood sugar control. Mounjaro tends to cost more.
How much weight can you lose on Mounjaro?
In the SURMOUNT-1 trial, people on 15 mg/week lost an average of 22.5% of their body weight over 72 weeks. At the lower 5 mg dose, weight loss was about 15%. Results vary by individual.
Is Mounjaro available in India?
Yes, Mounjaro (Eli Lilly) is available in India with a prescription for type 2 diabetes. Availability is growing in major cities. Cost ranges from ₹8,000–₹18,000 per month.
Can I switch from Ozempic to Mounjaro?
Yes, with your doctor's guidance. Typically you'd start Mounjaro at 2.5 mg regardless of your Ozempic dose, then titrate up. Your doctor will manage the transition.
How it works in your body
Tirzepatide activates both GIP and GLP-1 receptors. GLP-1 receptor activation reduces appetite and improves insulin secretion. GIP receptor activation enhances insulin sensitivity, may improve fat oxidation, and could help preserve lean mass. The combination produces additive effects on weight and glucose control.
Mounjaro vs Ozempic
| Mounjaro | Ozempic | |
|---|---|---|
| Drug | Tirzepatide | Semaglutide |
| Targets | GIP + GLP-1 | GLP-1 only |
| Max weight loss | ~22.5% | ~15–17% |
| HbA1c reduction | 2.0–2.4% | 1.0–1.8% |
| India cost (monthly) | ₹8,000–18,000 | ₹4,000–9,000 |
Biomarker monitoring
Same monitoring as semaglutide: HbA1c, fasting insulin, HOMA-IR, lipid panel, liver enzymes, kidney function, vitamin B12, and thyroid panel every 3–6 months.
Side effects & safety
Side effects are similar to semaglutide. GI symptoms are the most common and tend to improve over time.
- Nausea — 25–35% (slightly lower than semaglutide)
- Diarrhoea — 15–25%
- Constipation — 10–15%
- Decreased appetite — common and expected (it's part of how the drug works)
- Injection site reactions — mild in ~5% of users
- Muscle loss — same concern as all GLP-1 drugs
- Pancreatitis, gallbladder disease, thyroid C-cell tumours (same warnings as semaglutide)
- Contraindicated with personal/family history of MTC or MEN 2
- Seek emergency care for severe abdominal pain radiating to the back
Know what's working. Know what's not.
eterni connects your lab results, medications, and retests — so you can see the trajectory, not just a snapshot.
Join the waitlist